New immune globulin drug shows promise for rare nerve diseases in japan
NCT ID NCT05084053
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 study tested TAK-771, a combination of immune globulin and hyaluronidase, in 26 Japanese adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) or multifocal motor neuropathy (MMN). The main goals were to check for side effects and see how well the drug controls symptoms over up to 45 months. Participants received infusions every 2, 3, or 4 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TAK-771 (immune globulin infusion with hyaluronidase)
What this could lead to
If successful, TAK-771 could offer a new treatment option to help control symptoms of CIDP and MMN in Japanese patients.
What could go wrong
This is a small, completed Phase 3 study with only 26 participants, so results may not apply broadly. As with any immune globulin treatment, there is a risk of side effects like infusion reactions or blood clots.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (CIDP) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aichi Medical University Hospital
Nagakute, Aichi-ken, Japan
-
Asahikawa Medical Center
Asahikawa, Hokkaido, Japan
-
Chiba University Hospital
Chiba, Japan
-
Chubu Rosai Hospital
Nagoya, Aichi-ken, Japan
-
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
-
Higashimatsuyama Municipal Hospital
Saitama, Japan
-
Hiroshima University Hospital
Hiroshima, Japan
-
Hyogo College of Medicine Hospital
Nishinomiya, Hyōgo, Japan
-
Juntendo University Hospital
Bunkyo-ku, Tokyo, Japan
-
Kansai Rosai Hospital
Amagasaki, Hyōgo, Japan
-
Kumamoto University Hospital
Kumamoto, Japan
-
Kyushu University Hospital
Fukuoka, Japan
-
Nara Medical University Hospital
Kashihara, Nara, Japan
-
National Center of Neurology and Psychiatry
Kodaira, Tokyo, Japan
-
Shiga University of Medical Science Hospital
Ōtsu, Shiga, Japan
-
St.Marianna University School of Medicine Hospital
Kawasaki, Kanagawa, Japan
-
Toho University Omori Medical Center
Ōta-ku, Tokyo, Japan
-
Tohoku Medical and Pharmaceutical University Hospital
Sendai, Miyagi, Japan
-
Tokushima National Hospital
Yoshinogawa, Tokushima, Japan
-
Tokushima University Hospital
Tokushima, Japan
-
Tokyo Women's Medical University Hospital
Shinjuku-ku, Tokyo, Japan
-
Toyama University Hospital
Toyama, Japan
-
Yamaguchi University Hospital
Ube, Yamaguchi, Japan